Search results
Results from the WOW.Com Content Network
In addition to aripiprazole's partial agonism and functional selectivity characteristics, its effectiveness may be mediated by its very high dopamine D 2 receptor occupancy (approximately 31%, 44%, 75%, 80%, and 95% at daily dosages of 0.5 mg, 2 mg, 10 mg, 30mg and 40 mg respectively) [88] [89] Aripiprazole has been characterized as possessing ...
Neuroleptic malignant syndrome (Combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness, and sudden change in blood pressure and heart rate)
Dopamine agonists are mainly used to treat Parkinson's disease, but also hyperprolactinemia and restless legs syndrome. [15] The side effects are predominantly collected from studies of Parkinson's disease, where dopamine agonists are commonly used as a first-line treatment with levodopa. [16]
The latter have a greater degree of anticholinergic and antihistaminergic activity, which can counteract dopamine-related side-effects. [172] Atypical antipsychotic drugs have a similar blocking effect on D 2 receptors; however, most also act on serotonin receptors, especially 5-HT 2A and 5-HT 2C receptors. Both clozapine and quetiapine appear ...
more extrapyramidal side effects (EPS) and less antihistaminic effects (e.g. sedation), alpha adrenergic antagonism (e.g. orthostatic hypotension), and anticholinergic effects (e.g. dry mouth) middle: perphenazine and loxapine: intermediate D2 affinity, with more off-target effects than high-potency agents low: chlorpromazine
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The approval of aripiprazole lauroxil from the Food and Drug Administration in 2015 was solely for the treatment of schizophrenia in adults. The ability to supplement aripiprazole lauroxil with oral supplements of aripiprazole allows for dosing flexibility, which is important for the treatment of schizophrenia, as symptoms and intensity of the disease vary greatly from patient to patient.
It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. [1] [2] In July 2017, it was in preregistration in Japan for the treatment of MDD. [1] However, in September 2018, the regulatory submission in Japan for MDD was withdrawn. [3]